Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our Analyst Stock Ratings page. Traders can sort through Benzinga's extensive database of analyst ratings, including by analyst accuracy. Here's a look at the most recent high-yield dividend stock ratings from the most accurate Wall Street analysts, according to Benzinga's Analyst Stock Ratings.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Organon & Co. OGN

Dividend Yield: 5.36%
B of A Securities analyst Jason Gerberry downgraded the stock from Neutral to Underperform and cut the price target from $37 to $25 on Oct. 14, 2022. This analyst has an accuracy rate of 70%.
Piper Sandler analyst David Amsellem upgraded the stock from Neutral to Overweight and cut the price target from $37 to $34 on Sept. 6, 2022. This analyst has an accuracy rate of 71%.
Recent News: Organon reported worse-than-expected first-quarter adjusted EPS and sales results.

Viatris Inc. VTRS

Dividend Yield: 4.78%
BMO Capital analyst Gary Nachman downgraded the stock from Outperform to Market Perform and cut the price target from $16 to $14 on Feb. 17, 2023. This analyst has an accuracy rate of 69%.
Piper Sandler analyst David Amsellem upgraded the stock from Underweight to Neutral with a price target of $10 on Nov. 8, 2022. This analyst has an accuracy rate of 71%.
Recent News: Viatris posted better-than-expected earnings for its first quarter.

AbbVie Inc. ABBV

Dividend Yield: 4.31%
Guggenheim analyst Vamil Divan maintained a Buy rating and cut the price target from $172 to $171 on April 28, 2023. This analyst has an accuracy rate of 75%.
Wells Fargo analyst Mohit Bansal maintained an Overweight rating and slashed the price target from $200 to $195 on April 28, 2023. This analyst has an accuracy rate of 74%.
Recent News: The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending Abbvie's Atogepant for the prophylaxis of migraine in adults who have four or more migraine days per month.